Gastric ulcer
Conditions
Sponsors
Otsuka Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are H pylori positive and have active gastric ulcer, and aged 20 yeas or older at time of concent
Exclusion criteria
Exclusion criteria: 1. Patients who have previously received H. pylori eradication therapy 2. Patients with acute gastric ulcer 3. Patients with linear ulcer 4. Patients with complication of duodenal ulcer (excluding cicatrix) 5. Patients who have undergone upper-GI tract or vagal nerve resection 6. Patients who are unsuitable for pharmacotherapy, e.g., with perforation or pyloric stenosis 7. Patients with gastric ulcer considered likely to induce massive hemorrhage (e.g., with obviously exposed blood vessels at lesion sites) 8. Patients with a history of amoxicillin shock 9. Patients with infectious mononucleosis 10. Patients with severe renal disorders 11. Patients with a history of hypersensitivity to penicillins, clarithromycin, lansoprazole, or rebamipide 12. Patients who have been treated with drugs contraindicated to clarithromycin, such as terfenadine, cisapride, and pimozide 13. Patients who are pregnant, possibly pregnant, lactating, or who desire to become pregnant during the study 14. Patients who are otherwise judged inappropriate for inclusion in the study by the investigator or subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety efficacy Efficacy/safety | — |
Countries
Japan
Outcome results
None listed